ÐÔÊӽ紫ý

The Food and Drug Administration’s controversial June 7 approval of aducanumab (Aduhelm) means that for the first time in 18 years, Alzheimer’s patients have a new treatment option.

NervGen Pharma Corp., a clinical stage biotech company dedicated to creating innovative solutions for the treatment of nervous system damage, announced yesterday it has entered into a research collaboration with Dr. Ksenia Kastanenka of Massachusetts General Hospital (MGH) to study the effects of NervGen’s lead compound, NVG-291, in validated animal models of Alzheimer’s disease.

NervGen Pharma Corp., a clinical stage biotech company dedicated to creating innovative solutions for the treatment of nervous system damage, announced today it has entered into a research collaboration with Dr. Ksenia Kastanenka of Massachusetts General Hospital (MGH) to study the effects of NervGen's lead compound, NVG-291, in validated animal models of Alzheimer's disease.

The Food and Drug Administration’s approval of Biogen and Eisai’s anti-amyloid antibody aducanumab on June 7 left many questions unanswered, including how to use the drug in clinical practice.

Many doctors appear uneasy about prescribing Aduhelm, as they continue to grapple with a long list of unknowns.

Many doctors appear uneasy about prescribing Aduhelm, as they continue to grapple with a long list of unknowns.

A panel of experts has crafted guidance for clinical use of Aduhelm (aducanumab), the first targeted treatment for Alzheimer’s disease recently granted accelerated approval by the U.S. Food and Drug Administration (FDA).

Hallucinations and delusions are common in dementia and may be comorbid or part of the disease process (ie, dementia related psychosis [DRP]). DRP occurs in 30% of people with any type of dementia, 40% of those with Alzheimer disease and 70% of dementia with Lewy bodies.